Small molecule inhibitor of KRAS mutant protein

Compounds of formula (I) or pharmaceutically acceptable salts thereof can inhibit G12C, G12D and/or G12V mutants of Kirsteen rat sarcoma (KRAS) protein and are expected to be used, for example, as therapeutic agents for the treatment of cancer. The disclosure also provides pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof. The disclosure also relates to methods of using the compounds or pharmaceutically acceptable salts thereof in the treatment and prophylaxis of cancer and the preparation of medicaments for this purpose. 式(I)的化合物或其药学上可接受的盐可以抑制Kirsten大鼠肉瘤(KRAS)蛋白的G12C、G12D和/或G12V突变体，并有望用作例如用于治疗癌症的治疗剂。本公开还提供包含式(I)的化合物或其药学上可接受的盐的药物组合物。本公开还涉及将所述化合物或其药学上可接受的盐用于癌症的治疗和预防的方法以及制备用于此目的的药物。